MNKD: 2026 Pediatric Decision Will Shape Royalty Overhang And Rebound Potential

Analysts have updated their view on MannKind with a new fair value estimate of $4.75 per share, reflecting recent shifts in price targets as they balance concerns about Tyvaso DPI royalty risk against ongoing contributions from products like Furoscix and Afrezza.

Analyst Commentary

Recent research highlights a split in how professionals are valuing MannKind, with much of the debate centered on the durability of Tyvaso DPI royalties and how that uncertainty should be reflected in the share price.

Several firms point directly to the potential impact of United Therapeutics' planned soft mist inhaler for treprostinil, which could compete with Tyvaso DPI if it reaches the market. This has become a key swing factor in how analysts think about MannKind's medium term royalty and collaboration revenue stream.

Bearish Takeaways

Bearish analysts have reduced price targets on MannKind to levels such as US$8 from US$10 and US$7 from US$8, citing uncertainty around Tyvaso DPI royalties after United Therapeutics' soft mist inhaler announcement. They view this as a risk to future royalty and collaboration revenue assumptions.
One firm shifted MannKind to a more neutral rating and cut its price target to US$3.50 from US$7.50, arguing that the Tyvaso DPI royalty outlook could remain an overhang because key data may not be available until 2027. They see this as a headwind for valuation and investor confidence.
Bearish analysts describe United Therapeutics' planned soft mist inhaler as a material competitive risk that could potentially displace Tyvaso DPI if performance is comparable or better. They view this as a meaningful threat to MannKind's longer term growth profile tied to this franchise.
Several reports frame the recent share price selloff as reflecting concerns that MannKind may face migration risk within the Tyvaso franchise. These reports suggest investors could demand a larger discount until there is more clarity on long term royalty durability and execution on the 2026 product and pipeline plans.

Against this backdrop, some research argues that the sharp share price reaction could already be pricing in a worst case scenario for Tyvaso DPI. These perspectives see room for the stock to trade more on the performance of assets like Furoscix and Afrezza over time, while also acknowledging that uncertainty around Tyvaso DPI is likely to remain a central debate for valuation in the near term.

What’s in the News

MannKind plans to present new clinical and real world data for Afrezza Inhalation Powder at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2026) in Barcelona, including two oral presentations on post prandial glucose control across multiple studies and the INHALE 1 pediatric study, plus a poster on dosing and titration patterns in children and adolescents (Key Developments).
The FDA accepted for review a supplemental Biologics License Application for Afrezza in children and adolescents aged 4 to 17 with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026. If it is approved, Afrezza would become a needle free insulin option for pediatric patients (Key Developments).
Afrezza is currently indicated to improve glycemic control in adults with diabetes mellitus. It is administered at the beginning of meals via a small inhaler using Technosphere technology, with labeling that highlights its rapid onset and short duration as well as detailed safety information, including contraindications in chronic lung disease and a boxed warning on risk of acute bronchospasm (Key Developments).
Safety guidance for Afrezza emphasizes monitoring for hypoglycemia, pulmonary function decline measured by FEV1, potential hypokalemia, risk of heart failure when combined with TZDs, and the need to avoid use in patients with asthma, COPD, or a history of severe hypersensitivity to insulin products (Key Developments).

Valuation Changes

Fair Value Estimate updated to $4.75 per share from $3.85, indicating a higher assessed value for the stock.
Discount Rate adjusted slightly lower to 7.83% from 8.12%, implying a modest change in the required return used in the model.
Revenue Growth Assumption now set at 7.41% from 3.70%, reflecting a higher modeled growth rate for $ revenue.
Net Profit Margin Assumption reduced to 1.04% from 14.76%, indicating a much leaner profitability outlook in the current model.
Future P/E Multiple reset to 402x from 27x, signaling that a much higher earnings multiple is now being used in the valuation framework.

4 views

Key Takeaways

Limited awareness, slow market penetration, and rising competition from large pharma constrain growth and earnings potential, despite strong trends favoring MannKind's inhaled therapies.
Heavy dependence on a narrow pipeline, escalating expenses, and external pricing pressures threaten financial stability and delay meaningful profitability improvements.
Heavy reliance on few products, limited market penetration, emerging competition, high spending, and evolving regulatory pressures threaten revenue growth, margins, and long-term market positioning.

Catalysts

About MannKind

A biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States.What are the underlying business or industry changes driving this perspective?

While MannKind benefits from rising global diabetes prevalence and increasing patient preference for convenient, needle-free drug delivery with Afrezza, its ability to fully capitalize on these trends is constrained by slow expansion in formulary coverage, limited awareness among prescribers, and the challenge of building a larger, specialized sales force needed for both adult and pediatric markets. This is likely to suppress topline revenue growth and limit margin expansion into the near to medium term.
Although technological advances in digital health and remote monitoring create opportunities for innovative therapies like inhaled insulin, MannKind faces heightened competition from larger pharmaceutical firms with superior marketing and distribution capabilities, making significant market share gains in both diabetes and pulmonary indications uncertain and potentially impacting earnings stability.
While record Tyvaso DPI royalties and promising orphan lung pipeline developments highlight the potential of MannKind's Technosphere platform, the company's long-term financial health remains highly dependent on a narrow product portfolio, with clinical and regulatory risks around key new indications (such as inhaled clofazimine and nintedanib DPI) that could delay diversification and result in uneven revenue streams.
Despite securing flexible capital from Blackstone to fund late-stage pipeline and commercialization, MannKind continues to experience increasing R&D and selling expenses as it scales its infrastructure; if expected product and indication launches do not promptly generate material revenue, this could lead to a prolonged period of cash burn and insufficient operational leverage, threatening net margin improvements.
While government and payer support for value-based care and improved outcomes aligns with MannKind's inhaled therapies, there is the persistent threat of drug pricing pressures, growth in non-pharmacological solutions, and elongated approval timelines for new drug-device combinations, all of which may limit pricing power, delay revenue inflections, and hinder long-term sustainable profitability.

MannKind Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on MannKind compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming MannKind's revenue will grow by 7.4% annually over the next 3 years.
The bearish analysts assume that profit margins will increase from -6.6% today to 1.0% in 3 years time.
The bearish analysts expect earnings to reach $4.7 million (and earnings per share of -$0.28) by about May 2029, up from -$23.9 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $165.9 million.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 403.0x on those 2029 earnings, up from -42.8x today. This future PE is greater than the current PE for the US Biotechs industry at 16.2x.
The bearish analysts expect the number of shares outstanding to grow by 0.69% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.83%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

MannKind remains highly dependent on a handful of products, especially Tyvaso DPI royalties and Afrezza, and if new clinical data, regulatory hurdles, or payer pushback were to negatively impact either product, future revenues and earnings would be at risk given the limited diversification of income streams.
Despite recent growth, Afrezza's market penetration is still low relative to the overall rapid-acting insulin market, and the company acknowledges that lack of physician awareness and infrequent promotion could persistently restrict revenue expansion and impede long-term margin improvement.
Heightened industry competition, including the potential approval and commercialization of new inhaled or oral therapies for diabetes and pulmonary diseases by larger pharmaceutical companies, may limit MannKind's ability to gain or protect market share, adversely impacting future sales and reducing pricing power.
MannKind's increased R&D and commercial spending, combined with pipeline delays or clinical failures in late-stage programs like inhaled clofazimine or nintedanib DPI, could sustain high cash burn and necessitate further capital raises, leading to ongoing net margin pressure and potential shareholder dilution if revenue growth does not materialize as planned.
Global secular trends such as potential drug price controls, increased regulatory scrutiny, and the rise of digital and non-pharmacological diabetes management alternatives may erode profit margins and constrain revenue growth, particularly if reimbursement or adoption of inhaled therapeutics lags expectations over the long term.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for MannKind is $4.75, which represents up to two standard deviations below the consensus price target of $7.47. This valuation is based on what can be assumed as the expectations of MannKind's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $10.0, and the most bearish reporting a price target of just $4.75.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $447.0 million, earnings will come to $4.7 million, and it would be trading on a PE ratio of 403.0x, assuming you use a discount rate of 7.8%.
Given the current share price of $3.31, the analyst price target of $4.75 is 30.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on MannKind?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Slow Formulary Coverage Will Hamper Diabetes Reach Yet Enable Rebound